EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access · CC BY 4.0

Efficacy and Safety of Bilateral Deep Brain Stimulation ( DBS ) for Severe Alzheimer's Disease: A Comparative Analysis of Fornix Versus Basal Ganglia of Meynert

Junpeng Xu iD, Bin Liu, Guosong Shang, Zhebin Feng, Haonan Yang, Yuhan Chen, Xinguang Yu, Zhiqi Mao iD

CNS Neuroscience & Therapeutics · 2025

DOI: 10.1111/cns.70285 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Junpeng Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA, Beijing, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Basal Nucleus of Meynert, Deep Brain Stimulation, Fornix, Brain. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: STI 2030-Major Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Deep brain stimulation (DBS) is a novel therapy for severe Alzheimer's disease (AD). However, there is an ongoing debate regarding the optimal target for DBS, particularly the fornix and the basal ganglia of Meynert (NBM).

Objective

This study aimed to investigate the safety and efficacy of DBS for severe AD and to compare the fornix and the NBM as potential targets.

Methods

We conducted a prospective, nonrandomized clinical study involving 20 patients with severe AD (MMSE score 0 to 10, CDR level 3) from January 2015 to August 2022, comprising 12 males and eight females, with a mean age of 59.05 ± 6.45 years. All patients underwent DBS treatment, among which 14 received bilateral fornix implantation, while six received bilateral implantation in the NBM. Electrical stimulation commenced 1 month postoperatively. We assessed the patients before surgery, followed by evaluations at 1 month, 3 months, 6 months, and 12 months poststimulation. Primary outcome measures focused on changes in cognitive function, assessed using the MMSE, MoCA, ADAS‐Cog, and CDR scales. Secondary measures encompassed quality of life, caregiver burden, neuropsychiatric symptoms, and sleep disturbances, evaluated through the BI, FAQ, FIM, ZBI, NPI, HAMA, HAMD, and PSQI scales.

Results

All patients tolerated DBS well, with no serious adverse effects reported. Early on, DBS significantly improved cognitive function and quality of life. Long‐term benefits include the improvement of neuropsychiatric symptoms and sleep disorders and the alleviation of caregiver burden. Comparison between DBS targeting the NBM and fornix revealed no significant differences in overall scale scores. However, upon deeper analysis, NBM‐DBS exhibited a more pronounced improvement in neuropsychiatric symptoms, particularly in NPI scores.

Conclusion

DBS is a potential therapeutic approach for severe AD, capable of improving patients' cognitive function, quality of life, and neuropsychiatric symptoms. Notably, NBM‐DBS showed distinct advantages in ameliorating neuropsychiatric symptoms, providing valuable insights for clinically selecting the optimal DBS target. Trial Registration ClinicalTrials.gov identifier: NCT03115814

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBasal Nucleus of MeynertDeep Brain StimulationFornix, BrainAgedFemaleHumansMaleMiddle AgedProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

deep brain stimulationfornixnucleus basalis of Meynertsevere Alzheimer's disease

Autor:innen und Institutionen

  • Medical School of Chinese PLA, Beijing, China.
  • Department of Neurosurgery, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • PLA 942 Hospital, Yinchuan, China.
  • The First Clinical Medical College of Hebei North University, Zhangjiakou, China.

ORCID-Profile: Junpeng Xu, Zhiqi Mao

Förderung

  • STI 2030-Major Projects

Zitieren

APA

Xu, J., Liu, B., Shang, G., Feng, Z., Yang, H., Chen, Y., Yu, X., & Mao, Z. (2025). Efficacy and Safety of Bilateral Deep Brain Stimulation ( DBS ) for Severe Alzheimer's Disease: A Comparative Analysis of Fornix Versus Basal Ganglia of Meynert. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70285

Vancouver

Xu J, Liu B, Shang G, Feng Z, Yang H, Chen Y, et al. Efficacy and Safety of Bilateral Deep Brain Stimulation ( DBS ) for Severe Alzheimer's Disease: A Comparative Analysis of Fornix Versus Basal Ganglia of Meynert. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70285

BibTeX
@article{Xu2025,
  author = {Xu, Junpeng and Liu, Bin and Shang, Guosong and Feng, Zhebin and Yang, Haonan and Chen, Yuhan and Yu, Xinguang and Mao, Zhiqi},
  title = {Efficacy and Safety of Bilateral Deep Brain Stimulation ( DBS ) for Severe Alzheimer's Disease: A Comparative Analysis of Fornix Versus Basal Ganglia of Meynert},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  doi = {10.1111/cns.70285}
}
Kostenlos starten →